Curebase

High-Level Overview

Curebase is a modern, AI-powered clinical trial software platform designed to streamline and accelerate decentralized clinical trials (DCTs). It offers an integrated eClinical platform combining software tools such as electronic patient-reported outcomes (ePRO), electronic consent (eConsent), electronic data capture (EDC), and participant engagement features. Curebase serves sponsors, contract research organizations (CROs), and clinical sites, enabling them to launch studies faster, improve data quality, and enhance participant experiences. The platform is particularly strong in supporting digital therapeutics (DTx) trials with flexible virtual site models and extensive patient data capture capabilities, helping to democratize access to clinical trials by including more geographically and ethnically diverse participants[1][2][4].

For an investment firm, Curebase represents a company focused on transforming clinical research through technology innovation, emphasizing AI-driven efficiency and decentralized trial models. Its mission centers on democratizing clinical trials, accelerating drug and therapeutic development, and improving patient access. The company operates in the healthcare and life sciences sectors, particularly digital therapeutics and decentralized clinical trials, which are rapidly growing areas due to increasing demand for remote and hybrid trial solutions. Curebase’s impact on the startup ecosystem includes advancing digital health innovation and setting new standards for clinical trial execution through integrated software and services[1][2].

Origin Story

Curebase was founded in 2017 and participated in Y Combinator’s Summer 2018 batch. The company was founded by Storm Stillman, who previously co-founded Luminist Labs (acquired by DiscernDx) and currently serves as Curebase’s CEO. The idea emerged from the need to modernize clinical trials by leveraging AI and decentralized models to overcome traditional trial inefficiencies and accessibility barriers. Early traction included raising significant funding, such as a $40 million Series B round in 2022, and forming partnerships to expand trial capabilities, including collaborations with BEKhealth to enhance patient recruitment through AI-powered matching[2][3].

Core Differentiators

• AI-Powered Platform: Curebase integrates AI to automate and accelerate key clinical trial processes such as form building, data entry, and patient matching, improving speed and accuracy[2][9].
• Decentralized Clinical Trial Model: Supports remote and hybrid trials with virtual site models and digital recruitment strategies, enabling broader and more diverse patient participation[1][3].
• Integrated Software and Services: Combines ePRO, eConsent, EDC, and clinical trial execution services in one platform, reducing vendor complexity and streamlining trial management[1][4].
• Experienced Clinical Staff: In-house clinical research coordinators and principal investigators with expertise in digital therapeutic trials enhance trial quality and sponsor support[1].
• Flexible and Usable: Designed for full-study oversight with a focus on usability for sponsors, CROs, and sites, facilitating faster study launches and better participant engagement[2][7].

Role in the Broader Tech Landscape

Curebase rides the growing trend of decentralized clinical trials and digital therapeutics, driven by the need for more patient-centric, efficient, and inclusive clinical research. The timing is favorable due to advances in AI, increasing adoption of remote healthcare technologies, and regulatory support for decentralized trial models. Market forces such as rising costs of traditional trials, demand for faster drug development, and the need for diverse patient populations work in Curebase’s favor. By enabling decentralized trials and leveraging AI, Curebase influences the broader ecosystem by setting new standards for trial accessibility, data quality, and operational efficiency, thus accelerating innovation in healthcare and life sciences[1][2][3].

Quick Take & Future Outlook

Looking ahead, Curebase is poised to expand its platform capabilities, deepen AI integration, and broaden its therapeutic area coverage, including oncology and mental health trials. Trends shaping its journey include increasing regulatory acceptance of decentralized trials, growing digital therapeutics markets, and continued demand for patient-centric research models. Curebase’s influence is likely to grow as it helps sponsors and CROs adopt more flexible, efficient trial designs, potentially becoming a key enabler of faster, more inclusive clinical research worldwide. This aligns with its mission to democratize clinical trials and bring innovative therapies to patients faster[1][2][3].